Literature DB >> 18812222

BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro.

S M Shaw1, J E Fildes, C M Puchałka, M Basith, N Yonan, S G Williams.   

Abstract

BACKGROUND: The innate immune system plays an important role in cardiac allograft rejection. BNP has frequently been reported to elevate during acute cardiac rejection, yet the explanation behind this phenomenon is unclear. We hypothesized that BNP might interact with the innate immune system in cardiac transplant recipients and devised a series of in vitro culture experiments to explore this phenomena.
METHODS: PBMCs were isolated from whole blood of (total n = 40) cardiac transplant recipients. Short (24h, n = 20) and long term (72h, n = 20) co-cultures of innate cells in the presence or absence of BNP were performed. BNP was added at two specific concentrations and compared to placebo control. Innate cells were immunophenotyped using flow cytometry.
RESULTS: BNP dose dependently reduced the total number of monocytes, B cells and NK cells. Furthermore, BNP co-culture impaired NK cell cytotoxicity and adhesion of non-classical monocytes (via down-regulation of CD11c). DISCUSSION: BNP has an additional physiological role of moderating components of the innate immune system. Although speculative, this could be beneficial to cardiac transplant recipients as the innate immune system is involved in allograft rejection. Further investigation is required to elucidate the mechanism behind how BNP affects immune cells and whether the same effects are consistent with the adaptive immune system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812222     DOI: 10.1016/j.trim.2008.08.010

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  6 in total

1.  Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease.

Authors:  Cynthia S Crowson; Elena Myasoedova; John M Davis; Veronique L Roger; Barry L Karon; Daniel Borgeson; Richard J Rodeheffer; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

2.  Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD.

Authors:  Yi-Chun Tsai; Yi-Wen Chiu; Jer-Chia Tsai; Hung-Tien Kuo; Chi-Chih Hung; Shang-Jyh Hwang; Tzu-Hui Chen; Mei-Chuan Kuo; Hung-Chun Chen
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-15       Impact factor: 8.237

3.  The interaction between N-terminal pro-brain natriuretic peptide and fluid status in adverse clinical outcomes of late stages of chronic kidney disease.

Authors:  Yi-Chun Tsai; Hui-Ju Tsai; Chee-Siong Lee; Yi-Wen Chiu; Hung-Tien Kuo; Su-Chu Lee; Tzu-Hui Chen; Mei-Chuan Kuo
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

Review 4.  Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide?

Authors:  Nathalie Rosenblatt-Velin; Suzanne Badoux; Lucas Liaudet
Journal:  Stem Cells Int       Date:  2016-01-04       Impact factor: 5.443

Review 5.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.

Authors:  Shihui Fu; Ping Ping; Fengqi Wang; Leiming Luo
Journal:  J Biol Eng       Date:  2018-01-12       Impact factor: 4.355

6.  Potential Molecular Mechanism of the NPPB Gene in Postischemic Heart Failure with and without T2DM.

Authors:  Yao-Zong Guan; Rui-Xing Yin; Guo-Xiong Deng; Peng-Fei Zheng; Chun-Xiao Liu; Bi-Liu Wei
Journal:  Biomed Res Int       Date:  2020-08-03       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.